As of the latest trading close, MNKD, a Healthcare sector stock, is trading 1.57% below its 52-week high but remains 134.70% above its 52-week low. The Average True Range (ATR) (14 days) of 0.25 ...

In a report released on November 7, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind (MNKD – Research Report), ...

MannKind Corp (MNKD) reports a 37% revenue increase, driven by Tyvaso DPI and Afrezza, while navigating market challenges and ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...

MannKind Corp (NASDAQ:MNKD)的首席人事与工作场所官Stuart A. Tross最近出售了55,000股公司普通股。这笔交易发生于2024年11月6日，平均价格为每股7.34美元，总价值为403,700美元。此次出售后，Tross仍保留967,191股公司股份的所有权。这项交易是根据2024年5月31日制定的10b5-1规则计划进行的。 在其他近期新闻中，MannKind ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Leerink Partners has recently resumed MannKind Corp (MNKD) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on June 13, 2024, Rodman & Renshaw had initiated ...

MannKind Corporation (NASDAQ: MNKD) 公布了2024年第三季度强劲的财务业绩,收入同比增长37%,并取得重要的临床进展。公司首席执行官Michael Castagna强调了Tyvaso DPI合作项目的强劲表现以及Afrezza处方量的稳步上升。公司拥有2.68亿美元的现金储备,第三季度非GAAP营业收入为1500万美元,这使MannKind有能力推进其临床研发管 ...

MannKind (MNKD) reported $70.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 36.7%. EPS of $0.04 for the same period compares to $0.02 a year ago.

International Assets Investment Management LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 511 ...